Two Chinese research teams reported more worrisome findings regarding the MCR-1 resistance gene alongside other resistance factors, hinting at the presence of bacteria strains that may resist all drugs, and Canadian researchers said they dected the MCR-1 gene in a British Columbia patient.The two reports from China were published yesterday by separate teams in The Lancet Infectious Diseases.The MCR-1 gene, first described by Chinese investigators in November, disables the last-line antibiotic colistin, an older drug that isn’t often used in humans but is commonly used for raising food animals.In one study, researchers examined a collection of 17 colistin-resistant Enterobacteriaceae samples collected from 2013 through 2015 at a hospital in Suzhou, China. They found the MCR-1 gene in four isolates, two Escherichia coli and two Klebsiella pneumonia.Tests revealed that the two K pneumonia samples were resistant to all nearly all drugs tested, and both carried the NDM-5 resistance gene, a variant of NDM-1 that has increased carbapenemase activity.The scientists concluded that MCR-1 has already established itself in highly resistant Enterobacteriaeae species, including into carbapenem-resistant strains that carry the NDM-5 gene.In the second study from China, the other team did further analysis of E coli isolates from retail meat samples that carried the MCR-1 gene to see if they were resistant to other antibiotics. They found that one E coli strain from a chicken wing purchased in a large supermarket in 2014, was resistant to all antibiotics sampled except for doxycycline and tigecycline.The strain co-produced NDM-9 and another resistance gene, FosA3, which they wrote was surprising and worrisome, given that carbapenem and fosfomycin aren’t approved for use in food animals in China and that the strain’s presence in retail meat could colonize the human intestinal tract where it could transfer resistance to other pathogens.Findings in British ColumbiaElsewhere, researchers from British Columbia confirmed MCR-1 resistance in a patient who returned to the province from China, according to a Jan 25 statement from the BC Centre for Disease Control (CDC).The report didn’t say when the isolate was collected, but it noted that the sample is the second human case of MCR-1 resistance detected in Canada. The patient was successfully treated and was discharged from the hospital.According to BC CDC, the risk to British Columbia is low, the MCR-1 gene is rare in Canada, and the source is likely animals and meat sold in China or healthcare exposures outside of Canada.See also:Jan 31 Lancet Infect Dis report on MCR-1 in carbapenem-resistant EnterobacteriaceaeJan 31 Lancet Infect Dis report on carbapenem- and colistin-resistant E colico-producing NDM-9 and MCR-1Jan 25 BC CDC statement
Subscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.
Press Release, July 14, 2014; Image: james-fisher James Fisher – the UK’s marine services provider, announces the formation of a new venture with Aberdeen based company KDM Marine – James Fisher Mass Flow Excavation – to jointly offer their market-leading subsea excavation capability and resources to the offshore industry in a single entity.JFMFE combines the specialist subsea excavation, de-burial and trenching capabilities of both organisations and offers the extensive HydroDigger capability of James Fisher together with the highly innovative KDM TwinProp system to the offshore oil, gas and marine renewable energy sectors worldwide.Commenting on the formation of the JFMFE, Aidan Douglas, group operations director, James Fisher and Sons plc said “We are delighted to be able to offer our customers around the globe access to both the KDM TwinProp system and the extensive experience of Mass Flow Excavation applications, systems and technology that the KDM Marine management team have successfully built up over recent years”.Former KDM Marine chief executive and managing director of JFMFE, Kenneth Mackie, added “The resources and global footprint of James Fisher provides a strong platform to reach a number of international markets with our innovative technology. Our team is made up of some of the world’s leading Mass Flow Excavation specialists, responsible for the completion of over 300 projects. JFMFE has an impressive offering with the TwinProp and HydroDigger and we look forward to developing these tools’ positions in the marketplace”.